Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry

C. Okorn, A. Goertz, U. Vester, BB. Beck, C. Bergmann, S. Habbig, J. König, M. Konrad, D. Müller, J. Oh, N. Ortiz-Brüchle, L. Patzer, R. Schild, T. Seeman, H. Staude, J. Thumfart, B. Tönshoff, U. Walden, L. Weber, M. Zaniew, H. Zappel, PF. Hoyer,...

. 2019 ; 34 (6) : 1065-1075. [pub] 20190121

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023924

BACKGROUND: HNF1B gene mutations are an important cause of bilateral (cystic) dysplasia in children, complicated by chronic renal insufficiency. The clinical variability, the absence of genotype-phenotype correlations, and limited long-term data render counseling of affected families difficult. METHODS: Longitudinal data of 62 children probands with genetically proven HNF1B nephropathy was obtained in a multicenter approach. Genetic family cascade screening was performed in 30/62 cases. RESULTS: Eighty-seven percent of patients had bilateral dysplasia, 74% visible bilateral, and 16% unilateral renal cysts at the end of observation. Cyst development was non-progressive in 72% with a mean glomerular filtration rate (GFR) loss of - 0.33 ml/min/1.73m2 per year (± 8.9). In patients with an increase in cyst number, the annual GFR reduction was - 2.8 ml/min/1.73m2 (± 13.2), in the total cohort - 1.0 ml/min/1.73m2 (±10.3). A subset of HNF1B patients differs from this group and develops end stage renal disease (ESRD) at very early ages < 2 years. Hyperuricemia (37%) was a frequent finding at young age (median 1 year), whereas hypomagnesemia (24%), elevated liver enzymes (21%), and hyperglycemia (8%) showed an increased incidence in the teenaged child. Genetic analysis revealed no genotype-phenotype correlations but a significant parent-of-origin effect with a preponderance of 81% of maternal inheritance in dominant cases. CONCLUSIONS: In most children, HNF1B nephropathy has a non-progressive course of cyst development and a slow-progressive course of kidney function. A subgroup of patients developed ESRD at very young age < 2 years requiring special medical attention. The parent-of-origin effect suggests an influence of epigenetic modifiers in HNF1B disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023924
003      
CZ-PrNML
005      
20201214131723.0
007      
ta
008      
201125s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00467-018-4188-8 $2 doi
035    __
$a (PubMed)30666461
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Okorn, Christine $u Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany.
245    10
$a HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry / $c C. Okorn, A. Goertz, U. Vester, BB. Beck, C. Bergmann, S. Habbig, J. König, M. Konrad, D. Müller, J. Oh, N. Ortiz-Brüchle, L. Patzer, R. Schild, T. Seeman, H. Staude, J. Thumfart, B. Tönshoff, U. Walden, L. Weber, M. Zaniew, H. Zappel, PF. Hoyer, S. Weber,
520    9_
$a BACKGROUND: HNF1B gene mutations are an important cause of bilateral (cystic) dysplasia in children, complicated by chronic renal insufficiency. The clinical variability, the absence of genotype-phenotype correlations, and limited long-term data render counseling of affected families difficult. METHODS: Longitudinal data of 62 children probands with genetically proven HNF1B nephropathy was obtained in a multicenter approach. Genetic family cascade screening was performed in 30/62 cases. RESULTS: Eighty-seven percent of patients had bilateral dysplasia, 74% visible bilateral, and 16% unilateral renal cysts at the end of observation. Cyst development was non-progressive in 72% with a mean glomerular filtration rate (GFR) loss of - 0.33 ml/min/1.73m2 per year (± 8.9). In patients with an increase in cyst number, the annual GFR reduction was - 2.8 ml/min/1.73m2 (± 13.2), in the total cohort - 1.0 ml/min/1.73m2 (±10.3). A subset of HNF1B patients differs from this group and develops end stage renal disease (ESRD) at very early ages < 2 years. Hyperuricemia (37%) was a frequent finding at young age (median 1 year), whereas hypomagnesemia (24%), elevated liver enzymes (21%), and hyperglycemia (8%) showed an increased incidence in the teenaged child. Genetic analysis revealed no genotype-phenotype correlations but a significant parent-of-origin effect with a preponderance of 81% of maternal inheritance in dominant cases. CONCLUSIONS: In most children, HNF1B nephropathy has a non-progressive course of cyst development and a slow-progressive course of kidney function. A subgroup of patients developed ESRD at very young age < 2 years requiring special medical attention. The parent-of-origin effect suggests an influence of epigenetic modifiers in HNF1B disease.
650    _2
$a mladiství $7 D000293
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a chronické selhání ledvin $x genetika $7 D007676
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fenotyp $7 D010641
650    _2
$a polycystická choroba ledvin $x genetika $x patologie $x patofyziologie $7 D007690
650    _2
$a registrace $7 D012042
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Goertz, Anne $u Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Vester, Udo $u Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Beck, Bodo B $u Institute of Human Genetics, University Hospital of Cologne, Cologne, Germany. Cologne Center for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
700    1_
$a Bergmann, Carsten $u Bergmann Laboratory, University Medical Center Freiburg, Freiburg, Germany.
700    1_
$a Habbig, Sandra $u Pediatric Nephrology, University Children's Hospital Cologne, Cologne, Germany.
700    1_
$a König, Jens $u Pediatric Nephrology, University Children's Hospital Münster, Münster, Germany.
700    1_
$a Konrad, Martin $u Pediatric Nephrology, University Children's Hospital Münster, Münster, Germany.
700    1_
$a Müller, Dominik $u Pediatric Nephrology, University Campus Virchow University Children's Hospital Berlin, Berlin, Germany.
700    1_
$a Oh, Jun $u Pediatric Nephrology, University Children's Hospital Hamburg, Hamburg, Germany.
700    1_
$a Ortiz-Brüchle, Nadina $u Institute of Human Genetics, RWTH University Hospital Aachen, Aachen, Germany.
700    1_
$a Patzer, Ludwig $u Children's Hospital St. Elisabeth and St. Barbara, Halle (Saale), Germany.
700    1_
$a Schild, Raphael $u Pediatric Nephrology, University Children's Hospital Hamburg, Hamburg, Germany.
700    1_
$a Seeman, Tomas $u Pediatric Nephrology, University Children's Hospital Prague, Prague, Czech Republic.
700    1_
$a Staude, Hagen $u Pediatric Nephrology, University Children's Hospital Rostock, Rostock, Germany.
700    1_
$a Thumfart, Julia $u Pediatric Nephrology, University Campus Virchow University Children's Hospital Berlin, Berlin, Germany.
700    1_
$a Tönshoff, Burkhard $u Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
700    1_
$a Walden, Ulrike $u Children's Hospital Augsburg, Augsburg, Germany.
700    1_
$a Weber, Lutz $u Pediatric Nephrology, University Children's Hospital Cologne, Cologne, Germany.
700    1_
$a Zaniew, Marcin $u Department of Pediatrics, University of Zielona Góra, Zielona Góra, Poland.
700    1_
$a Zappel, Hildegard $u University Children's Hospital Göttingen, Göttingen, Germany.
700    1_
$a Hoyer, Peter F $u Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Weber, Stefanie $u Pediatric Nephrology, University Children's Hospital Marburg, Baldingerstrasse 1, 35033, Marburg, Germany. Stefanie.weber@med.uni-marburg.de.
773    0_
$w MED00003733 $t Pediatric nephrology (Berlin, Germany) $x 1432-198X $g Roč. 34, č. 6 (2019), s. 1065-1075
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30666461 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131720 $b ABA008
999    __
$a ok $b bmc $g 1596243 $s 1114600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 34 $c 6 $d 1065-1075 $e 20190121 $i 1432-198X $m Pediatric nephrology $n Pediatr Nephrol $x MED00003733
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace